AJ Foyt Racing Signs Charlie Kimball for the Indianapolis 500 and the Indy Grand Prix in May



WALLER, Texas (Feb. 11, 2021) --- AJ Foyt Racing announced today that Charlie Kimball will be back in the cockpit for two races in the 2021 NTT INDYCAR Series. The 35-year-old Californian will pilot the team’s No. 11 Tresiba® Chevrolet in the 105th running of the Indianapolis 500 on May 30 after competing in the Indy Grand Prix on the IMS road course on May 15.


For the 13th consecutive season, Kimball will partner with his longtime sponsor, Novo Nordisk, a global healthcare company, as part of the company’s Race with Insulin initiative. Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL is the insulin Charlie takes to manage his type 1 diabetes. Novo Nordisk has sponsored Kimball every year since his 2009 debut in the Indy Lights presented by Cooper Tire Series. Kimball debuted in the NTT INDYCAR Series in 2011.


“I am excited to once again represent Novo Nordisk and the diabetes community and to join AJ Foyt Racing for the month of May,” Kimball said. “I have never run at Indianapolis without Novo Nordisk and to be able to return this year with the support of the legendary A.J. Foyt, Larry Foyt, and everyone at AJ Foyt Racing, will certainly be special.”


For the month of May, Kimball will be part of a three-car effort from the Texas-based team, partnering with Sebastien Bourdais in the No. 14 Chevrolet and Dalton Kellet in the No. 4 Chevrolet. Kimball ran the full 2020 season with Foyt and closed it out finishing eighth in St. Petersburg, Florida.


"It's awesome to have Charlie and Novo Nordisk back for the month of May,” said Larry Foyt, president of A.J. Foyt Racing. “They were both great to work with throughout the challenges of 2020, and I'm glad we can continue the program. Charlie is focused on producing great results, and we are working hard to put the best group together for success."


Kimball at speed on the road course at Indy last year.


In 155 races, Kimball has posted six podium (top-three) finishes, and an additional eight top-fives. He has finished in the top-10 (6ththrough 10th) 45 times and has led 163 laps.


“Over the last 13 years, Charlie Kimball and Race with Insulin have become an important part of Novo Nordisk,” said Chip Amrein, lifecycle management and connected care lead. “We are pleased to join AJ Foyt Racing for both the Indianapolis Grand Prix and the Indianapolis 500 this year and to continue supporting Charlie as an ambassador and inspiration within the diabetes community.”

About Tresiba®


Tresiba® Indication and Important Safety Information


What is Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL?


· Prescription Tresiba® is a long-acting insulin used to control high blood sugar in adults and children who are 1 year of age and older with diabetes


· Tresiba® is not for people with diabetic ketoacidosis


· It is not known if Tresiba® is safe and effective in children under 1 year of age


· Tresiba® is available in 2 concentrations: 200 units/mL and 100 units/mL


Important Safety Information


Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.


Who should not take Tresiba®?


Do not take Tresiba® if you:


· are having an episode of low blood sugar


· are allergic to Tresiba® or any of the ingredients in Tresiba®


Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:


· pregnant, planning to become pregnant, or are breastfeeding


· taking new prescription or over-the-counter medicines, vitamins, or herbal supplements


Talk to your health care provider about low blood sugar and how to manage it.


How should I take Tresiba®?


· Read the Instructions for Use and take Tresiba® exactly as your health care provider tells you to


· Do not do any conversion of your dose. The dose counter always shows the selected dose in units


· Know the type and strength of insulin you take. Do not change the type of insulin you take unless your health care provider tells you to


· Change (rotate) your injection sites within the area you choose with each injection to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.


o Do not use the exact same spot for each injection.


o Do not inject where the skin has pits, is thickened, or has lumps.


o Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.


· Adults - If you miss or are delayed in taking your dose of Tresiba®:


o Take your dose as soon as you remember, then continue with your regular dosing schedule


o Make sure there are at least 8 hours between doses


· If children miss a dose of Tresiba®:


o Call the healthcare provider for information and instructions about checking blood sugar levels more often until the next scheduled dose of Tresiba®


· For children who need less than 5 units of Tresiba® each day, use a Tresiba® U100 vial


· Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them


· Do not reuse or share your needles or syringes with other people. You may give them a serious infection, or get a serious infection from them


· Never inject Tresiba® into a vein or muscle


· Never use a syringe to remove Tresiba® from the FlexTouch® pen


What should I avoid while taking Tresiba®?


· Do not drive or operate heavy machinery, until you know how Tresiba® affects you

· Do not drink alcohol or use prescription or over-the-counter medicines that contain alcohol


What are the possible side effects of Tresiba®?

Tresiba® may cause serious side effects that can be life-threatening, including:


· Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include anxiety, irritability, mood changes, dizziness, sweating, confusion, and headache


· Low potassium in your blood (hypokalemia)


· Heart failure in some people if taken with thiazolidinediones (TZDs). This can happen even if you have never had heart failure or heart problems. If you already have heart failure, it may get worse while you take TZDs with Tresiba®. Tell your health care provider if you have any new or worse symptoms of heart failure including shortness of breath, tiredness, swelling of your ankles or feet, and sudden weight gain


Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.


Common side effects may include reactions at the injection site, itching, rash, serious allergic reactions (whole body reactions), skin thickening or pits at the injection site (lipodystrophy), weight gain, and swelling of your hands and feet.


Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.


Selected Important Safety Information


Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.


Who should not take Tresiba®?


Do not take Tresiba® if you:


· are having an episode of low blood sugar


· are allergic to Tresiba® or any of the ingredients in Tresiba®


Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:


· pregnant, planning to become pregnant, or are breastfeeding


· taking new prescription or over-the-counter medicines, vitamins, or herbal supplements


Talk to your health care provider about low blood sugar and how to manage it. How should I take Tresiba®?


· Read the Instructions for Use and take Tresiba® exactly as your health care provider tells you to


· Do not do any conversion of your dose. The dose counter always shows the selected dose in units


· Know the type and strength of insulin you take. Do not change the type of insulin you take unless your health care provider tells you to


· Change (rotate) your injection sites within the area you choose with each injection to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.


o Do not use the exact same spot for each injection.


o Do not inject where the skin has pits, is thickened, or has lumps.


o Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.


Please see Prescribing Information for Tresiba® at https://www.novo-pi.com/tresiba.pdf


About Novo Nordisk

Novo Nordisk is a global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 5,000 people throughout the country. For more information, visit novonordisk.us, Facebook, Instagram and Twitter.


About AJ Foyt Racing

AJ Foyt Racing, located 20 miles northwest of Houston, has been competing at the top levels of motorsports since December 1965, over 50 years. With Foyt driving, his team won two Indianapolis 500s and three national Indy car championships. Since his retirement from driving in 1993, the team has continued to win, claiming two more national titles and the 1999 Indianapolis 500 with driver Kenny Brack. To date, they have amassed 44 victories and 45 pole positions.




Tresiba® and Race With Insulin® are registered trademarks of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective

owners.


© 2021 Novo Nordisk All rights reserved. US21TSM00030 February 2021


Featured Posts
Recent Posts
Archive
Search By Tags
  • Facebook - White Circle
  • Twitter - White Circle
  • Instagram - White Circle

© 2020 by A.J. FOYT ENTERPRISES

Refund Policy  Privacy Policy  Terms of Use